Spinal muscular atrophy treatment

Spinal Muscular Atrophy Microchapters
Home
Patient Info
Overview
Epidemiology and Demographics
Risk Factors
Screening
Other forms
Molecular Biology
Genetics
Types
Diagnosis
Diagnosis
Full Differential Diagnosis
Symptom
Physical Examination
Electrolyte & Biomarker Studies
Electrocardiogram
Chest X Ray
MRI and CT
Echocardiography or Ultrasound
Other Imaging Findings
Pathology
Other Diagnostic Studies
Treatment
Outcome measures
Therapeutics development
Indications For Surgery
Research
Pre-Operative Assessment
Post-Operative Assessment
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Spinal muscular atrophy treatment Resources
Most recent articles on Spinal muscular atrophy treatment
Most cited articles on Spinal muscular atrophy treatment
Review articles on Spinal muscular atrophy treatment
Review articles on Spinal muscular atrophy treatment
CME Programs on Spinal muscular atrophy treatment
Powerpoint slides on Spinal muscular atrophy treatment
Images of Spinal muscular atrophy treatment
Ongoing Trials on Spinal muscular atrophy treatment at Clinical Trials.gov
US National Guidelines Clearinghouse on Spinal muscular atrophy treatment
NICE Guidance on Spinal muscular atrophy treatment
FDA on Spinal muscular atrophy treatment
CDC on Spinal muscular atrophy treatment
Spinal muscular atrophy treatment in the news
Blogs on Spinal muscular atrophy treatment
Directions to Hospitals Treating Spinal muscular atrophy treatment
Risk calculators and risk factors for Spinal muscular atrophy treatment

Editors-in-Chief: C. Michael Gibson, M.S., M.D.; Priyamvada Singh, MBBS

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

The course of SMA is directly related to the severity of weakness. Infants with the severe form of SMA frequently succumb to respiratory disease due to weakness of the muscles that support breathing. Children with milder forms of SMA naturally live much longer although they may need extensive medical support, especially those at the more severe end of the spectrum.

Although gene replacement strategies are being tested in animals, current treatment for SMA consists of prevention and management of the secondary effect of chronic motor unit loss. It is likely that gene replacement for SMA will require many more years of investigation before it can be applied to humans. Due to molecular biology, there is a better understanding of SMA. The disease is caused by deficiency of SMN (survival motor neuron) protein, and therefore approaches to developing treatment include searching for drugs that increase SMN levels, enhance residual SMN function, or compensate for its loss.

Much can be done for SMA patients in terms of medical and in particular respiratory, nutritional and rehabilitation care. However, there is currently no drug known to alter the course of SMA. Significant progress has been made in preclincial research towards an effective treatment. Several drugs have been identified in laboratory experiments that hold promise for patients. To evaluate if these drugs benefit SMA patients, clinical trials are needed. In a clinical trial a new medication is tested while the patients are carefully monitored for their safety and for any possible drug effects, positive or negative.

Some drugs under clinical investigation for the treatment of SMA:

• Butyrates
• Valproic acid
• Hydroxyurea
• Riluzole